Neurocrine Biosciences, Inc. (NBIX) Earnings History
Annual and quarterly earnings data from 1996 to 2025
Loading earnings history...
NBIX EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
NBIX Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 98.2% | 21.6% | 16.7% |
| 2024 | 98.6% | 24.2% | 14.5% |
| 2023 | 97.9% | 13.3% | 13.2% |
| 2022 | 98.4% | 16.7% | 10.4% |
| 2021 | 98.7% | 9.0% | 7.9% |
Download Data
Export NBIX earnings history in CSV or JSON format
Free sign-in required to download data
Neurocrine Biosciences, Inc. (NBIX) Earnings Overview
As of May 8, 2026, Neurocrine Biosciences, Inc. (NBIX) reported trailing twelve-month net income of $669M, reflecting +41.9% year-over-year growth. The company earned $6.47 per diluted share over the past four quarters, with a net profit margin of 16.7%.
Looking at the long-term picture, NBIX's 5-year EPS compound annual growth rate (CAGR) stands at +2.3%, reflecting modest earnings expansion. The company achieved its highest annual net income of $479M in fiscal 2025, representing a new all-time high.
Neurocrine Biosciences, Inc. maintains industry-leading profitability with a gross margin of 98.2%, operating margin of 21.6%, and net margin of 16.7%. This margin structure demonstrates strong pricing power and operational efficiency. View revenue history →
Compared to peers including INVA ($504M net income, 63.8% margin), ACAD ($376M net income, 36.5% margin), PTCT (-$187M net income, 39.4% margin), NBIX has room to improve margins relative to the peer group. Compare NBIX vs INVA →
NBIX Earnings vs Peers
Earnings metrics vs comparable public companies
NBIX Historical Earnings Data (1996–2025)
30 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $479M | +40.2% | $619M | $4.67 | 16.7% | 21.6% |
| 2024 | $341M | +36.7% | $571M | $3.29 | 14.5% | 24.2% |
| 2023 | $250M | +61.6% | $251M | $2.47 | 13.2% | 13.3% |
| 2022 | $155M | +72.4% | $249M | $1.56 | 10.4% | 16.7% |
| 2021 | $90M | -78.0% | $103M | $0.92 | 7.9% | 9.0% |
| 2020 | $407M | +1000.8% | $163M | $4.16 | 38.9% | 15.6% |
| 2019 | $37M | +75.3% | $72M | $0.39 | 4.7% | 9.2% |
| 2018 | $21M | +114.8% | $37M | $0.22 | 4.7% | 8.2% |
| 2017 | -$143M | -1.0% | -$131M | $-1.62 | -88.2% | -81.3% |
| 2016 | -$141M | -58.7% | -$147M | $-1.63 | -940.6% | -982.5% |
Full NBIX Stock Analysis
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
See NBIX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs NBIX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare NBIX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonNBIX — Frequently Asked Questions
Quick answers to the most common questions about buying NBIX stock.
Is NBIX growing earnings?
NBIX EPS is $6.47, with earnings growth accelerating to +41.9%. This exceeds the 5-year CAGR of +2.3%. TTM net income reached $669M.
What are NBIX's profit margins?
Neurocrine Biosciences, Inc. net margin is +16.7%, with operating margin at +21.6%. Above-average margins indicate pricing power.
How consistent are NBIX's earnings?
NBIX earnings data spans 1996-2025. The accelerating earnings trend is +41.9% YoY. Historical data enables comparison across business cycles.